These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Medulloblastoma: time-dose relationship based on a 30-year review. del Charco JO, Bolek TW, McCollough WM, Maria BL, Kedar A, Braylan RC, Mickle JP, Buatti JM, Mendenhall NP, Marcus RB. Int J Radiat Oncol Biol Phys; 1998 Aug 01; 42(1):147-54. PubMed ID: 9747832 [Abstract] [Full Text] [Related]
14. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A. Int J Radiat Oncol Biol Phys; 2008 Mar 01; 70(3):782-7. PubMed ID: 17892918 [Abstract] [Full Text] [Related]
18. Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy? Burcu A, Nazan Ç, Özgür Ö, Serra K, Mehmet K, Serap A, Bengü D, Canan V, Haldun Ö, Savaş K, Tuncer T, Taner A, Yeşim E, Ömer K, Yavuz A. Childs Nerv Syst; 2018 Sep 01; 34(9):1657-1662. PubMed ID: 29868932 [Abstract] [Full Text] [Related]